CYRX Rule 144 Notice — 9,300 Common Shares to Be Sold via Morgan Stanley

Rhea-AI Filing Summary

CryoPort, Inc. (CYRX) Form 144 notice: The filing reports a proposed sale of 9,300 common shares, with an aggregate market value of $80,617.98, from a total of 50,066,968 shares outstanding. The shares are to be sold on 08/19/2025 on NASDAQ through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. The filing states the shares were acquired on 08/19/2025 by exercise of options under a registered plan and were paid for in cash. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.

Positive

• Transaction documented under Rule 144: Notice filed indicating compliance with Rule 144 sale procedures.
• Acquisition and payment disclosed: Shares were acquired by exercise of options under a registered plan and paid for in cash on 08/19/2025.
• Broker-dealer identified: Sale to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider-originated sale via Rule 144 after option exercise; transaction appears routine and compliance-focused.

The Form 144 discloses a notice to sell 9,300 common shares through a registered broker-dealer on 08/19/2025. The shares were acquired the same day through exercise of options under a registered plan and paid in cash, and the filer indicates no sales in the prior three months. From a securities-market perspective, this is a standard Rule 144 disclosure for an affiliate disposing of shares following an option exercise and uses an established brokerage channel.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 mechanics and includes the required attestation about material non-disclosure.

The filing includes the statutory representation that the seller does not possess undisclosed material adverse information and notes no prior three-month sales. It also documents acquisition details (exercise under a registered plan) and payment method (cash), which align with routine insider transaction reporting and internal governance expectations for transparency around equity disposals.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9300	80617.98	50066968	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/19/2025	Exercise of options under a registered plan	Issuer			9300	08/19/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CYRX Form 144 report?

The filing reports a proposed sale of 9,300 common shares of CryoPort (CYRX) with an aggregate market value of $80,617.98 to be sold on 08/19/2025 on NASDAQ.

How were the CYRX shares acquired?

The shares were acquired on 08/19/2025 by exercise of options under a registered plan and payment was made in cash.

Which broker will execute the CYRX sale?

The sale is to be executed through Morgan Stanley Smith Barney LLC, Executive Financial Services at 1 New York Plaza, 8th Floor, New York, NY.

Were any CYRX shares sold by the filer in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

What attestation does the filer make on the Form 144?

The filer represents by signing the notice that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.